跳至主要内容
临床试验/NCT00134238
NCT00134238终止3 期

Phase 3 Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Mixed Hyperlipidemia

Pfizer51 个研究点 分布在 6 个国家目标入组 755 人开始时间: 2003年11月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
终止
发起方
Pfizer
入组人数
755
试验地点
51
主要终点
Change in intima media thickness as measured by carotid ultrasound

研究概览

简要总结

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at ultrasound images taken in the carotid arteries and to look at various lipids in the blood of people with mixed hyperlipidemia

详细描述

For additional information please call: 1-800-718-1021

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of mixed hyperlipidemia
  • At least 18 years of age

排除标准

  • Women who are pregnant or lactating, or planning to become pregnant.
  • Subjects with a clinically indicated need for statin (HMG-CoA reductase inhibitor) therapy other than atorvastatin or other concomitant therapy with known lipid altering effects on LDL-C and HDL-C including fibrates and nicotinic acid (high doses)
  • Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
  • Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluationof response, or render unlikely that the subject would complete the study

结局指标

主要结局

Change in intima media thickness as measured by carotid ultrasound

次要结局

  • Changes in levels of lipids and other biomarkers.

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (51)

Loading locations...

相似试验